Analyst Upgrades Signal Renewed Growth Cycle for Edwards Lifesciences Corporation (EW)

Edwards Lifesciences Corporation (NYSE:EW) is one of the best healthcare stocks to buy for 2026. On January 20, Stifel raised its price target of Edwards Lifesciences Corporation (NYSE:EW) to $110 from $105 while reiterating a Buy rating.

The price target hike is in response to a significant increase in the number of Transcatheter Aortic Valve Replacement (TAVR) procedures. After surveying physicians who perform the procedure, the results indicate significant growth in TAVR. Likewise, the results point to improvement in TAVR market fundamentals. The results align with the company’s revenue growing by 10% in the third quarter, driven by growth in the TAVR division, which accounts for 75% of total revenue. It is the strongest growth for the division in recent years.

Earlier, on January 9, TD Cowen upgraded Edwards Lifesciences to a Buy from Hold and raised the price target to $97 from $90. The price target hike is in response to the company entering what the research firm touts as a renewed growth cycle, driven by expanded indications for transcatheter aortic valve replacement (TAVR).

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company that develops and provides patient-focused innovations for heart conditions, specializing in structural heart disease (artificial heart valves, repair devices for mitral/tricuspid valves) and critical care monitoring.

While we acknowledge the potential of EW as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 12 Best Consumer Goods Stocks Billionaires Are Quietly Buying and Goldman Sachs Penny Stocks: Top 12 Stock Picks.

Disclosure: None. This article is originally published at Insider Monkey.